There’s been much conversation recently about the fate of value-based purchasing and the move from fee-for-service to outcomes-based medicine. Established by the Patient Protection and Affordable Care Act (ACA), the Hospital Value-Based Purchasing (VBP) Program is an initiative set forth by the Centers for Medicare & Medicaid Services (CMS) to provide acute-care hospitals with incentive payments based on the quality of care provided to their Medicare beneficiaries. These payments are based not only on how well the hospitals perform on each approved measure, but also on how much they improve compared with their performance that was established during a predetermined baseline period.
If you are a regular reader of our blog, you know we use a number of terms quite often. Fiercely unbiased. Critical appraisal. Scientific rigor.
But whether you’re a payer or a provider, a current or potential client: what does any of that mean to you? Why are these terms important, and how can the fact that they make up the DNA of what we do enhance your coverage policy determination and value analysis and value-based purchasing initiatives?
We are pleased to announce our lineup of guest speakers for this year’s Client Symposium. In addition to our keynote speaker, we are featuring two professionals who bring years of healthcare expertise and experience to our second annual gathering in the city of brotherly love.
The credentials of these sought-after presenters speak for themselves, so I’m going to let them do just that. Once you’ve read about their impressive backgrounds and accomplishments, head over to our registration page and reserve your spot at the Client Symposium today!
Last week, as part of their “Your Health” segment, NPR aired a piece about the effectiveness of various treatments for low back pain, with a focus on spinal manipulation. Lower back pain is a common complaint to physicians, and, as the article states, a common reason for the prescription of addictive narcotic painkillers. Other interventions can include:
- Physical therapy
- Massage therapy
- Nonsteroidal anti-inflammatory drugs (NSAIDS)
- Chiropractic treatment
Hayes is a company of real people and we’d like you to get to know us. This month, we introduce you to another valuable contributor to the Hayes mission of providing fiercely unbiased evidence. Meet Beth Bontemps.
Ms. Bontemps joined Hayes in September 2014 as a Senior Analyst. In 2017, she was promoted to the position of Product Manager, Prognosis and News Service.
She comes to Hayes from JR Associates Inc., a medical technology reimbursement consulting firm where she worked as a clinical and reimbursement consultant.
Topics: Hayes Blog
Who doesn’t love lists? Especially lists detailing the best of the best, the most popular, the most in-demand. To that end, we’ve compiled a list of our top three Directory reports for the first three months of the year, in order of retrievals from our Knowledge Center. These three represent a mix of information important to both payers and providers.
If you’re already a subscriber, you can check out these reports at any time. If you’re not a Hayes member…what are you waiting for? Don’t forget, you can also purchase an individual report. Contact us to find out how.
Let’s get to the top three!
Last week, I had the distinct privilege of presenting the keynote at the first annual Northeast Regional Conference of the Association of Healthcare Value Analysis Professionals (AHVAP). With the ever-increasing push away from fee-for-service and toward value-based healthcare, I thought it pertinent to discuss the role of value analysis in the success of a health system’s bundled payment initiatives. Specifically, I wanted to highlight the role evidence can play in assisting value analysis professionals in their evidence-based decision making, as well as how it can help them define the part they play in the value-based purchasing environment.
In early March, Becker’s Hospital Review reported that MD Anderson Cancer Center placed their Oncology Expert Advisor project on hold. Announced in 2013, the joint effort between the hospital and the software giant was to be a revolutionary step forward in the use of “big data” to significantly improve clinical decision making and healthcare delivery. The article cites a number of reasons as to why the initiative was sidelined, not the least of which was cost. However, according to the article, a far more interesting complication arose involving MD Anderson’s electronic health record (EHR) system, which was changed after the program had begun. IBM Watson’s technology no longer communicated with the new EHR system and therefore had outdated information.
Traditional cancer treatments include procedures with which we’re all familiar: chemotherapy, surgery, and radiation therapy. But clinicians and scientists continue to work tirelessly to find a cure for the devastating disease. While immunotherapy has been in the news as of late as relates to the treatment of peanut allergies (see our blog, Peanut Allergy Drug Therapies Make National Headlines), there have been advances in its use for the treatment of cancer over the past few years. There are several biologic agents that are FDA approved for different cancers; these targeted therapies are aimed at destroying cancer cells without the troublesome side effects that accompany traditional cancer treatments.
But there’s something new on the horizon from the world of immunotherapy.
We’ve reached the final stretch of our physician engagement blog. Thanks for sticking with us! By now, we hope you’ve already applied some of our suggestions as to how to improve your physician buy-in. Don’t forget to share this blog with your supply chain and value analysis peers as well as the physicians in your hospital or health system. While you’re here, download our companion eBook for a lighthearted look at the challenges of physician engagement. Who couldn’t use a good laugh?
Let’s wrap up part 4 with our final piece of advice!